Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Influencers on TikTok have been banned after they were found to be promoting drugs like Ozempic and Mounjaro through their social media ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc. (“Launchit”) are pleased to announce that the Company, Launchit and ...

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Louisiana is facing a significant obesity challenge, ranking fourth in the nation for obesity rates. As a result, many residents are turning to weight loss drugs like ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

People using Ozempic say they are losing their desire to drink. It’s anecdotal evidence right now, but this would be a game-changer for those who are trying to break free from addiction.

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...